Alnylam Pharmaceuticals (ALNY) vs BridgeBio Pharma (BBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BridgeBio Pharma (BBIO) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 11.6% versus a loss of 67.0%. Over five years, BBIO leads with a +92.2% price change compared with -23.7% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($19.26 billion vs $14.81 billion), about 1.3 times the size, while BridgeBio Pharma is growing revenue faster (+126.3% vs +65.2%).
Alnylam Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.4% versus -146.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | BBIO |
|---|---|---|
| Share price | $143.82 | $76.03 |
| Market cap | $19.26B | $14.81B |
| 1-day change | -2.71% | -2.75% |
| YTD return | -63.83% | -0.60% |
| 1-year return | -67.04% | +11.63% |
| 5-year return | -23.72% | +92.24% |
| P/E ratio (TTM) | 7.26 | — |
| Forward P/E | 14.51 | — |
| EPS (TTM) | $19.80 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | $502.08M |
| Revenue growth (YoY) | +65.19% | +126.26% |
| Net income (latest FY) | $313.75M | $-732.94M |
| Gross margin | 81.77% | 95.82% |
| Operating margin | 13.51% | -104.25% |
| Net margin | 8.45% | -145.98% |
| 52-week high | $479.79 | $93.42 |
| 52-week low | $143.40 | $62.50 |
| Distance from 52-week high | -70.02% | -18.61% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +101.10% | +40.73% |
| Average volume | 2.09M | 2.67M |
| Shares outstanding | 133.94M | 194.80M |
| Employees | 2,500 | 1,081 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BBIO has outperformed ALNY by 78.7 percentage points over the past year.
- Alnylam Pharmaceuticals is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
- BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +65.19%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees
ALNY vs BBIO FAQ
Which is bigger, Alnylam Pharmaceuticals or BridgeBio Pharma?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $19.26B compared with $14.81B for BridgeBio Pharma (BBIO).
Which stock has performed better over the past year, ALNY or BBIO?
BBIO returned +11.63% over the past 12 months, compared with -67.04% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Are Alnylam Pharmaceuticals and BridgeBio Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.